Mark Pollack to Escherichia coli
This is a "connection" page, showing publications Mark Pollack has written about Escherichia coli.
Connection Strength
0.282
-
Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992 Jan; 165(1):34-45.
Score: 0.104
-
Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983 Dec; 72(6):1874-81.
Score: 0.059
-
Lipopolysaccharide (LPS)-specific monoclonal antibodies regulate LPS uptake and LPS-induced tumor necrosis factor-alpha responses by human monocytes. J Infect Dis. 1995 Sep; 172(3):794-804.
Score: 0.033
-
Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O polysaccharide and core regions of Escherichia coli lipopolysaccharide. J Infect Dis. 1994 Mar; 169(3):553-61.
Score: 0.030
-
Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. J Infect Dis. 1992 Oct; 166(4):803-11.
Score: 0.027
-
Specificity and function of monoclonal antibodies reactive with discrete structural elements of bacterial lipopolysaccharide. Adv Exp Med Biol. 1990; 256:331-40.
Score: 0.023
-
Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages. J Infect Dis. 1989 May; 159(5):872-80.
Score: 0.005